

A1  
Out

2. (Amended) The rodent bone metastasis model animal according to claim 1, wherein the tumor cells are human lung cancer or breast cancer derived cells highly expressing PTHrP.

3. (Amended) The rodent bone metastasis model animal according to claim 1, wherein the tumor cells are cells from human lung small cell carcinoma.

4. (Amended) The rodent bone metastasis model animal according to claim 1, which exhibits multi-organ metastasis of tumor cells.

5. (Amended) The rodent bone metastasis model animal according to claim 4, wherein the multi-organ metastases include metastases to one or more organs selected from lung, liver, kidney, and lymph node.

A2

7. (Amended) The rodent bone metastasis model animal according to claim 1, wherein the animal is a mouse.

A3

9. (Amended) The rodent bone metastasis model animal according to claim 7, wherein the animal is a SCID mouse.

10. (Amended) A method for producing a rodent exhibiting bone metastasis of tumor cells, comprising:

(i) providing a rodent having reduced immunity; and

(ii) introducing tumor cells that induce bone metastasis into the animal by

peripheral administration.

A4

13. (Amended) The method according to claim 10, wherein the step of providing a rodent having reduced immunity includes a step of inactivating NK cells in the animal.

A4  
Out

14. (Amended) The method according to claim 10, wherein the step of providing a rodent having reduced immunity includes a step of reducing the number of NK cells in the animal.

15. (Amended) The method according to claim 10, wherein the step of providing a rodent having reduced immunity includes a step of depleting NK cells in the animal.

16. (Amended) The method according to claim 10, wherein the step of providing a rodent having reduced immunity includes a step of administering anti-IL-2 receptor antibody to the animal.

sub  
C4

24. (Amended) A method for evaluating efficiencies of treatment against bone metastasis of tumor cells, comprising:

(i) applying a treatment to the rodent bone metastasis model animal according to any one of claims 1 to 5, 7, or 9; and

(ii) comparing the size and/or extent of bone metastasis, and/or symptoms resulted from bone metastasis, with a control animal.

A3

25. (Amended) A method for determining the effect of a test substance on bone metastasis, comprising:

(i) administering the test substance to the rodent bone metastasis model animal according to any of claims 1 to 5, 7, or 9; and

(ii) comparing the size and/or extent of bone metastasis, and/or symptoms resulted from bone metastasis, with a control animal.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000